Photo of David Qian, PhD

David Qian PhD

  • (503) 312-5912
    • Assistant Professor of Medicine School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Dr. Qian’s laboratory studies the molecular and cellular mechanism of chemotherapy stress response and resistance and the epigenetics of hypoxia. The lab is investigating ways to target prostate cancer cells and angiogenesis with HDAC inhibitors.  Dr. Qian also performs research in the Beer Lab.

Education

  • Ph.D., The Johns Hopkins University School of Public Health, Baltimore Maryland 2002

Memberships and associations

  • American Association for Cancer Research

Publications

  • "Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy." Nature communications  In: , Vol. 9, No. 1, 4972, 01.12.2018.
  • "microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1." Journal of Cellular Biochemistry  In: , 01.01.2018.
  • "Systemic Inhibition of CREB is Well-tolerated in vivo." Scientific Reports  In: , Vol. 6, 34513, 03.10.2016.
  • "Can post-transcription modifiers change the course of prostate cancer?"   Prostate Cancer: Translational and Emerging Therapies. CRC Press, 2016. p. 179-194.
  • "Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity." Journal of Medicinal Chemistry  In: , Vol. 58, No. 12, 25.06.2015, p. 5075-5087.
  • "Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase." Biochimica et Biophysica Acta - Molecular Cell Research  In: , Vol. 1853, No. 5, 01.05.2015, p. 881-891.
  • "Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer." Clinical Cancer Research  In: , Vol. 20, No. 5, 2014, p. 1306-1312.
  • "Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism." Prostate  In: , Vol. 73, No. 10, 07.2013, p. 1028-1037.
  • "HIF1α protein stability is increased by acetylation at lysine 709." Journal of Biological Chemistry  In: , Vol. 287, No. 42, 12.10.2012, p. 35496-35505.
  • "Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours." British Journal of Cancer  In: , Vol. 106, No. 1, 03.01.2012, p. 77-84.
  • "HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia." Journal of Biological Chemistry  In: , Vol. 286, No. 44, 04.11.2011, p. 38095-38102.
  • "A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma." Science Translational Medicine  In: , Vol. 3, No. 85, 85ra47, 01.06.2011.
  • "Cigarette smoke and cancer." Journal of Oncology  In: , 2011.
  • "Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer." Cancer Research  In: , Vol. 70, No. 20, 15.10.2010, p. 7992-8002.
  • "ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21 (Cancer Research (2010) 70, (3239-3248) DOI : 10.1158/0008-5472. CAN-09-3186)." Cancer Research  In: , Vol. 70, No. 11, 01.06.2010, p. 4785.
  • "ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21." Cancer Research  In: , Vol. 70, No. 8, 15.04.2010, p. 3239-3248.
  • "CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity." Prostate  In: , Vol. 70, No. 4, 01.03.2010, p. 433-442.
  • "Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 106, No. 42, 20.10.2009, p. 17910-17915.
  • "Prostate cancer - Associated gene expression alterations determined from needle biopsies." Clinical Cancer Research  In: , Vol. 15, No. 9, 01.05.2009, p. 3135-3142.
  • "Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 106, No. 7, 17.02.2009, p. 2353-2358.
  • "Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 105, No. 50, 16.12.2008, p. 19579-19586.
  • "The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells." Clinical Cancer Research  In: , Vol. 14, No. 11, 01.06.2008, p. 3562-3570.
  • "Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors." Clinical Cancer Research  In: , Vol. 14, No. 11, 01.06.2008, p. 3589-3597.
  • "Platelets take up the monoclonal antibody bevacizumab." Clinical Cancer Research  In: , Vol. 13, No. 18, 15.09.2007, p. 5341-5347.
  • "The N-Myc down regulated gene1 (NDRG1) is a Rab4a effector involved in vesicular recycling of E-cadherin." PLoS One  In: , Vol. 2, No. 9, e844, 05.09.2007.
  • "Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models." Prostate  In: , Vol. 67, No. 11, 01.08.2007, p. 1182-1193.
  • "Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs." Cancer Chemotherapy and Pharmacology  In: , Vol. 60, No. 3, 08.2007, p. 329-339.
  • "Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model." Clinical Cancer Research  In: , Vol. 13, No. 14, 15.07.2007, p. 4201-4208.
  • "Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma." Molecular Cancer Therapeutics  In: , Vol. 6, No. 1, 01.2007, p. 70-81.
  • "Identification of ABR-215050 as lead second generation quinoline-3- carboxamide anti-angiogenic agent for the treatment of prostate cancer." Prostate  In: , Vol. 66, No. 16, 01.12.2006, p. 1768-1778.

Additional information

Edit profile